Canadian application, no grantCanada
Angiopoietin-2 specific binding agents
CA 2461435 A1 · Owner: Amgen Inc. · Inventors: Oliner, Jonathan Daniel
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are specific binding agents, such as fully human antibodies that , bind to angiopoietin-2. Also disclosed are heavy chain fragments light chain , fragments, and CDRs of the antibodies as well as methods of making and using the antibodies.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 11, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 11, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 11, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledOctober 11, 2002
GrantedNo grant recorded
Term endedOctober 11, 2022
Patent numberCA 2461435 A1
Classification (IPC)C12N15/13 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.